Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM. Recently, neuroprotective effects of glucagon-like peptide-1 (GLP-1) are reported. In this study, we explored whether liraglutide, a GLP-1 analogue exerts therapeutic effects on a rat stroke model. Wistar rats received occlusion of the middle cerebral artery for 90 min. At one hour after reperfusion, liraglutide or saline was administered intraperitoneally. Modified Bederson’s test was performed at 1 and 24 h and, subsequently, rats were euthanized for histological investigation. Peripheral blood was obtained for measurement of blood glucose level and evaluation of oxidative stress. Brain tissues were collected to evaluate the level of vascular endothelial growth factor (VEGF). The behavioral scores of liraglutide-treated rats were significantly better than those of control rats. Infarct volumes of liraglutide-treated rats at were reduced, compared with those of control rats. The level of derivatives of reactive oxygen metabolite was lower in liraglutide-treated rats. VEGF level of liraglutide-treated rats in the cortex, but not in the striatum significantly increased, compared to that of control rats. In conclusion, this is the first study to demonstrate neuroprotective effects of liraglutide on cerebral ischemia through anti-oxidative effects and VEGF upregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Sato et al. [66] demonstrated upregulation of VEGF in the cerebral cortex of liraglutide-treated rats subjected to MCAO; however, this was not seen within the striatum [66].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681 · cited 1×
“table; grade 2: decreased resistance to lateral push (and forelimb flexion) without circling; grade 3: same behavior as grade 2, with circling [28,29].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 3×
“Moreover, anti-inflammatory effects of liraglutide might have also influenced the results of this study, as shown in previous Alzheimer’s disease research [10].”
BackgroundResultLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“disease mouse model, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which might also suggest that therapeutic effects of exenatide were strongly related to anti-oxidative effects [8].”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Furthermore, lixisenatide, a newly developed GLP-1 analogue exerted stronger neurogeneic effects than liraglutide on Alzheimer’s disease rodent model, although both agents breached the blood brain barrier and were bioavailable in the brain with subsequent neurogeneic effects [20].”
BackgroundHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · cited 1×
“In several studies, neurogeneic effects of liraglutide were shown, in that the administration of liraglutide, as well as exenatide, resulted in enhanced proliferation of progenitor cells with a subsequent increase in young neurons in the dentate gyrus of high-fat-diet-fed mice [18] and Alzheimer’s disease mouse model…”
BackgroundBorlongan, C. V., Kaneko, Y., Maki, M., Yu, S.-J., Ali, M., Allickson, J. G., Sanberg, C. D., Kuzmin-Nichols, N., & Sanberg, P. R. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0340 · Cited by 205 · cited 1×
“Further studies are needed to explore the expression of other neurotrophic factors to fully recognize the therapeutic potential of liraglutide, in view of accumulating evidence that neurohumoral factors secreted from various cells are key to the neuroprotective and neurorestorative effects of cell-based therapies for…”
BackgroundSelf-citationTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundMcClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · cited 1×
“The same group revealed that administration of liraglutide enhances long term potentiation and suppressed the deterioration of long term potentiation in Alzheimer’s disease rat model [11].”
BackgroundPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 1×
“Recently, neuroprotective effects of exenatide, which has 52% homologous amino-acid sequence to GLP-1, were reported in several studies [1,3].”
Result
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Sato et al. found that intraperitoneal injection of liraglutide 2.5 h after stroke induced neuroprotection in rats, which was related to the upregulation of vascular endothelial growth factor (VEGF) (86).”
BackgroundInfluentialThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Zhu, H., Zhang, Y., Shi, Z., Lu, D., Li, T., Ding, Y., Ruan, Y., & Xu, A. (2016) · Scientific Reports · doi:10.1038/srep26859 · Cited by 183
Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction
Nian, K., Harding, I. C., Herman, I. M., & Ebong, E. E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.605398 · Cited by 165
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
GLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
Weina, H., Yuhu, N., Christian, H., Birong, L., Feiyu, S., & Le, W. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.031 · Cited by 115
Toyoshima, A., Yasuhara, T., Kameda, M., Morimoto, J., Takeuchi, H., Wang, F., Sasaki, T., Sasada, S., Shinko, A., Wakamori, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127302 · Cited by 111
“We evaluated the mean infarct area ratio of 2 sections (n = 29) [11, 30, 31].”
MethodSelf-citationBriyal, S., Shah, S. Z., & Gulati, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.064 · Cited by 109
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103
Ji, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 105
“…processes in PD. GLP-1 analogues have shown neuroprotective effects in various diseases, such as Alzheimer’s disease, Parkinson’s disease, head trauma or stroke (Darsalia et al., 2012; Holscher, 2013; McClean and Holscher, 2014; Perry and Greig, 2004; Sato et al., 2013; Tweedie et al., 2013).”
BackgroundCrosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 111
“A recent meta‐analysis revealed that treatment with probiotics significantly decreased common risk factors of NAFLD and cardiometabolic syndrome.(168) It is obvious that there is a robust association between microbiota changes and the development of NAFLD and possibly cardiometabolic syndrome via sharing common pathwa…”
BackgroundXie, Z., Enkhjargal, B., Wu, L., Zhou, K., Sun, C., Hu, X., Gospodarev, V., Tang, J., You, C., & Zhang, J. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.040 · Cited by 96
“GLP-1R agonists have been reported to be neuroprotective in various diseases of the CNS (Hou et al., 2012; Kuroki et al., 2016; Rachmany et al., 2013; Sato et al., 2013; Teramoto et al., 2011; Zhu et al., 2016).”
BackgroundInfluentialWiciński, M., Socha, M., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 89
Sebastião, I., Candeias, E., Santos, M. S., de Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00110 · Cited by 92
“Similar to liraglutide, lixisenatide also crosses the BBB into CNS, whereby it has been shown to exert strong neurogenic effects in an AD rodent model (124, 141) (Figure 1), as well as to prevent Aβ-related impaired synaptic plasticity, hippocampal LTP, and spatial learning memory in a PI3K/Akt/GSK-3β-mediated pathway…”
BackgroundDuarte, A. I., Candeias, E., Alves, I. N., Mena, D., Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 90
Cao, L., Li, D., Feng, P., Li, L., Xue, G.-F., Li, G., & Hölscher, C. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000548 · Cited by 90
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 86
Deng, C., Cao, J., Han, J., Li, J., Li, Z., Shi, N., & He, J. (2018) · Computational Intelligence and Neuroscience · doi:10.1155/2018/3094504 · Cited by 73
“suggested that liraglutide reduced neuronal damage caused by cerebral ischemia in diabetic and nondiabetic rats through antioxidative stress and antiapoptosis pathways [5].”
BackgroundVergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“GLP-1RAs also reduced several other markers of oxidative stress in rodent stroke models, such as blood and brain ROS counts, blood levels of derivatives of reactive oxygen metabolites (d-ROMs), and brain levels of dihydroethidium, a marker of ROS production [66, 87].”
BackgroundMethodBasalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68
Kong, F., Wu, J., Sun, S., Ma, L., & Zhou, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.001 · Cited by 69
“Moreover, liraglutide displayed neuroprotection against neurologic disorders in animal models of cerebral ischemia (Zhu et al., 2016), AD (Qi et al., 2016), traumatic brain injury (Li et al., 2015a,b), and stroke (Sato et al., 2013).”
Panagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 61
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 63
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“A single administration of liraglutide post- stroke decreased MCAO-induced infarction with behavioral improvement, and the neuroprotective effects of liraglutide in normoglycemic rats may be due to suppression of oxidative stress and upregulation of VEGF in the cerebral cortex, but not striatum (105).”
BackgroundHeydarpour, F., Sajadimajd, S., Mirzarazi, E., Haratipour, P., Joshi, T., Farzaei, M. H., Khan, H., & Echeverría, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.498758 · Cited by 62
“Mounting evidence has been supported the anticancer, anti-bacterial, anti-fungal, anti-viral, anti-inflammatory, immunomodulatory and hepatoprotective properties of propolis (Banskota et al., 2001; Gülçin et al., 2010; Sawicka et al., 2012; Chan et al., 2013).”
BackgroundHakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
“It has been reported that Liraglutide effectively improves sensorimotor function 24–72 hours post injury when, assessed by a variety of neuroscore tests, in different models of experimental stroke [8,13].”
BackgroundFukuda, S., Nakagawa, S., Tatsumi, R., Morofuji, Y., Takeshita, T., Hayashi, K., Tanaka, K., Matsuo, T., & Niwa, M. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0696-1 · Cited by 53
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“demonstrated upregulation of VEGF in the cerebral cortex of liraglutide-treated, normoglycemic rats; however, this was not seen within the striatum.(32) Markers of neuronal, glial and endothelial function (NeuN, GFAP and vWF respectively) were used by Dong et al.”
MethodZhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
Zhang, Y., Chen, Y., Li, L., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.021 · Cited by 51
Ma, J., Shi, M., Zhang, X., Liu, X., Chen, J., Zhang, R., Wang, X., & Zhang, H. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3509 · Cited by 47
“Therefore, there is a requirement to identify novel drugs and targets for alleviating DPN. Glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, is a type of GLP-1 derivative that has a 97% homologous amino-acid sequence to GLP-1, with the addition of a fatty acid (8).”
Wei, J., Yang, B., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1007980 · Cited by 44
“Furthermore, GLP1RA also reduces the inflammatory cytokines TNF-a, IL-1b and IL-6 (29), GLP-1RAs are also proposed to have antioxidant and neuroprotective effects by upregulating vascular endothelial growth factor production (30) and reducing proinflammatory cytokine production (31).”
BackgroundLim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
“More directly, intracerebroventricular administration of liraglutide reduced the cerebral infarct volume in rats with ischaemia– reperfusion injury.(63) GLP-1RAs are also proposed to have antioxidant and neuroprotective effects by upregulating vascular endothelial growth factor production(63) and reducing proinflammat…”
BackgroundToots, M., Seppa, K., Jagomäe, T., Koppel, T., Pallase, M., Heinla, I., Terasmaa, A., Plaas, M., & Vasar, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-28314-z · Cited by 52
Zhang, Y., Ma, L., Su, Y., Su, L., Lan, X., Wu, D., Han, S., Li, J., Kvederis, L., Corey, S., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146432 · Cited by 47
Self-citationDarsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
“2 Interestingly, Sato et al13 showed that liraglutide administered intraperitoneally 2.5 hours after stroke onset induced neuroprotection in the rat in correlation with VEGF upregulation.13 As for the works of Teramoto et al and Darsalia et al described above, the data are clinically relevant since efficacy could be a…”
MethodInfluentialHan, L., Hölscher, C., Xue, G.-F., Li, G., & Li, D. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000490 · Cited by 43
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
“onset induced neuroprotection in the rat in correlation with vascular endothelial growth factor (VEGF) up-regulation (Sato et al., 2013) (Briyal et al.”
BackgroundPotentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 43
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
Insulin in the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Cerecedo-Lopez, C. D., Cantu-Aldana, A., Patel, N. J., Aziz-Sultan, M. A., Frerichs, K. U., & Du, R. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.01.056 · Cited by 40
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 39
“GLP-1 analogues have shown neuroprotective effects in various diseases, such as Alzheimer's disease, Parkinson's disease, head trauma or stroke (Darsalia et al., 2012; Holscher, 2013; McClean and Holscher, 2014; Perry and Greig, 2004; Sato et al., 2013; Tweedie et al., 2013).”
BackgroundQi, Q., Lu, L., Li, H., Yuan, Z., Chen, G., Lin, M., Ruan, Z., Ye, X., Xiao, Z., & Zhao, Q. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s132064 · Cited by 38
“37 Finally, liraglutide reduces myocardial apoptosis.”
Li, Y., Xu, B., Yang, J., Wang, L., Tan, X., Hu, X., Sun, L., Chen, S., Zhu, L., Chen, X., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105867 · Cited by 36
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 38
“A single administration of liraglutide acutely after reperfusion has been shown to reduce infarct volumes in a transient MCAO model [125].”
BackgroundCitraro, R., Iannone, M., Leo, A., Caro, C. D., Nesci, V., Tallarico, M., Abdalla, K., Palma, E., Arturi, F., Sarro, G. D., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.001 · Cited by 38
“Accordingly, several preclinical studies have demonstrated anti-apoptotic, anti-inflammatory, anti-oxidant and neuroprotective effects of LIR against stroke (Sato et al., 2013), Parkinson’s disease (Liu et al.”
BackgroundNeuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries
Dergunova, L. V., Filippenkov, I. B., Limborska, S. A., & Myasoedov, N. F. (2023) · Genes · doi:10.3390/genes14050953 · Cited by 40
Ravassa, S., Beaumont, J., Huerta, A., Barba, J., Coma-Canella, I., González, A., López, B., & Díez, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.01.002 · Cited by 34
Chen, Y., Zhang, X., He, J., Xie, Y., & Yang, Y. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.12.015 · Cited by 32
Protective roles of bioactive peptides during ischemia-reperfusion injury: From bench to bedside
Wu, D., Wang, J., Wang, H., Ji, A., & Li, Y. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.05.014 · Cited by 32
Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy
Wen, Y., Wu, K., Xie, Y., Dān, W., Zhan, Y., & Shi, Q. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.028 · Cited by 33
GLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 31
“showed that liraglutide administered 90 min after stroke reperfusion induced neuroprotection in the rat [109].”
BackgroundFilchenko, I., Simanenkova, A., Chefu, S., Kolpakova, M., & Vlasov, T. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118788079 · Cited by 28
Tu, X.-K., Chen, Q., Chen, S., Huang, B., Ren, B., & Shi, S.-S. (2020) · Inflammation · doi:10.1007/s10753-020-01344-4 · Cited by 32
Neuroprotective Effects of a Novel Antioxidant Mixture Twendee X in Mouse Stroke Model
Kusaki, M., Ohta, Y., Inufusa, H., Yamashita, T., Morihara, R., Nakano, Y., Liu, X., Shang, J., Tian, F., Fukui, Y., et al. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.01.003 · Cited by 30
Self-citationDong, W., Miao, Y., Chen, A., Cheng, M., Ye, X., Song, F., & Zheng, G. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.045 · Cited by 29
Langlois, A., Mura, C., Bietiger, W., Seyfritz, E., Dollinger, C., Péronet, C., Maillard, É., Pinget, M., Jeandidier, N., & Sigrist, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147068 · Cited by 30
“Indeed, recent studies revealed that GLP-1 enhanced the proliferation and differentiation of endothelial progenitor cells via upregulation of VEGF [18].”
BackgroundZhang, W.-Q., Tian, Y., Chen, X.-M., Wang, L.-F., Chen, C.-C., & Qiu, C.-M. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0392-8 · Cited by 27
Yabuno, S., Yasuhara, T., Nagase, T., Kawauchi, S., Sugahara, C., Okazaki, Y., Hosomoto, K., Sasada, S., Sasaki, T., Tajiri, N., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03236-4 · Cited by 31
“We evaluated cerebral infarct area ratio by the following method: Cerebral infarct area ratio = [LT – (RT – RI)] × 100/LT (%), where LT is the area of the left hemisphere in mm2, RT is the area of the right hemisphere in mm2, and RI is the infarct area in mm2 [35, 42, 43].”
MethodSelf-citationProtective effect of rhGLP-1 (7–36) on brain ischemia/reperfusion damage in diabetic rats
Zhao, L., Xu, J., Wang, Q., Qian, Z., Feng, W., Yin, X., & Fang, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.014 · Cited by 31
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28
“Long-lasting peptide analogues such as liraglutide and exenatide were identified and investigated, and the neuroprotective efficiency of these analogs was also reported (Lee et al., 2011; Teramoto et al., 2011; Briyal et al., 2012; Darsalia et al., 2012; Darsalia et al., 2013; Sato et al., 2013; Yang et al., 2013; Hol…”
BackgroundAbdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 28
Xie, Z., Enkhjargal, B., Matei, N., Wu, L., Zhu, Q., Zhang, T., Tang, J., & Zhang, J. H. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750726 · Cited by 28
“In the past few years, other studies of GLP-1R have suggested this receptor to be a promising therapeutic target in various CNS diseases (Teramoto et al., 2011; Hou et al., 2012; Rachmany et al., 2013; Sato et al., 2013; Kuroki et al., 2016; Zhu et al., 2016).”
BackgroundFang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C. (2018) · Drug Development Research · doi:10.1002/ddr.21439 · Cited by 21
“In another study, liraglutide ameliorated behavioral scores and alleviated cerebral infarct volume and oxidative stress parameters as well as increasing cortical vascular endothelial growth factor levels (Sato et al., 2013).”
BackgroundGonzález-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
Gad, S. N., Nofal, S., Raafat, E. M., & Ahmed, A. A. E. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01497-9 · Cited by 18
“GLP-1 analogues such as exenatide and liraglutide showed anti-inflammatory and antiapoptotic effects when tried in neurodegenerative diseases and cerebral ischemic models (Grieco et al. 2019; Sato et al. 2013; Wicinski et al. 2019).”
BackgroundLiraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
Yang, L., Cheng, J., Shi, G., Zhang, C., Du, Y., Chen, L., Qiao, H., Chen, R., & Zhang, X. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03574-4 · Cited by 18
“2A and B), consistent with previous studies [29, 30].”
ResultCurrent Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration
Fakoya, A. O. J., Otohinoyi, D. A., & Yusuf, J. A. (2018) · Stem Cells International · doi:10.1155/2018/3123961 · Cited by 19
“However, the short half-life (13 hours) of liraglutide limits its clinical applicability, thus necessitating repeated subcutaneous injections [209, 210].”
BackgroundStand alone or join forces? Stem cell therapy for stroke
Abraham, D. I., Gonzales, M., Ibarra, A., & Borlongan, C. V. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1551872 · Cited by 19
Self-citationHe, W., Tian, X., Lv, M., & Wang, H. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.05.039 · Cited by 17
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 17
Neuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury
Jiang, D., Wang, Y., Zang, Y., Liu, X., Zhao, L., Wang, Q., Liu, C., Feng, W., Yin, X., & Fang, Y. (2016) · Drug Development Research · doi:10.1002/ddr.21297 · Cited by 17
“GLP-1 and its analogs can also provide neuroprotection against cerebral ischemia and reverse impairments in cognitive processes in rodent models of Alzheimer’s disease (AD) [Briyal et al., 2012; McClean et al., 2010; McClean and Holscher, 2014; Sato et al., 2013].”
BackgroundNeuroprotective role of (Val 8 ) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
Liu, Y., Li, L., Liu, K., Zhao, J., Hölscher, C., & Li, G. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177742 · Cited by 15
Age-related change of GLP-1R expression in rats can be detected by [18F]AlF-NOTA-MAL-Cys39-exendin-4
Wang, L., Liu, Y., Xu, Y., Sheng, J., Pan, D., Wang, X., Yan, J., Yang, R., & Yang, M. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.022 · Cited by 15
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
Ahn, C. H., & Lim, S. K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00038 · Cited by 14
“After cerebral ischemia-reperfusion injury, intraperitoneal or intracerebroventricular administration of liraglutide, a GLP1 analogue, consistently reduced the cerebral infarct volume in rats.(78) These neuroprotective effects are induced by increasing antioxidant effects, upregulating vascular endothelial growth fact…”
BackgroundLee, J.-Y., Castelli, V., Bonsack, B., García-Sánchez, J., Kingsbury, C., Nguyen, H., Tajiri, N., & Borlongan, C. V. (2020) · Cell Transplantation · doi:10.1177/0963689720905805 · Cited by 14
Self-citationBell, D. S. H., & Gonçalves, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108199 · Cited by 14
Bellomo, T. R., Hwang, C. D., Spector‐Bagdady, K., Stanley, J. C., & Corriere, M. A. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.09.053 · Cited by 13
Shi, N., He, J. N., Guo, Q., Liu, T., & Han, J. (2019) · Neuroreport · doi:10.1097/wnr.0000000000001225 · Cited by 13
Michaelsen, M. K., Drasbek, K. R., Valentin, J. B., Svart, M. V., Larsen, J. B., Kruuse, C. R., Simonsen, C. Z., & Blauenfeldt, R. A. (2025) · Stroke · doi:10.1161/strokeaha.125.053075 · Cited by 15
Fang, Y., Liu, X., Zhao, L., Wei, Z., Jiang, D., Shao, H., Zang, Y., Xu, J., Wang, Q., Liu, Y., et al. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.5.475 · Cited by 13
“It has been reported recently that GLP-1 receptor agonists (Exendin-4 / liraglutide) have neuroprotective effect on cerebral ischemia models [17-20], they could reduce tissue stress injury and reduce brain infarction volume, possibly through anti-oxidative effects and anti-apoptotic effects; as such, they may have a f…”
BackgroundDeciphering the brain glucose metabolism: A gateway to innovative stroke therapies
Pisani, D. F., & Blondeau, N. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251346277 · Cited by 13
“125 As explained previously, both hyper-and hypogly-caemia can induce ROS production, mitochondrial dysfunction and extracellular glutamate accumulation, and thereby aggravate stroke consequences.”
The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion
Yalçın, M. B., Bora, E. S., & Erbaş, O. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46010021 · Cited by 11
“Prospective randomized studies can be conducted on the EMG outcomes.”
BackgroundLi, Y., & Gong, M. (2021) · Brain and Behavior · doi:10.1002/brb3.2190 · Cited by 10
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 20
“As such, intracerebroventricular administration of GLP-1RA has been shown to reduce cerebral infarct volume in rats subjected to ischemia – reperfusion injury [32,36].”
Mechanisms of neuroprotective action of incretin mimetics
Vlasov, T. D., Симаненкова, А. В., Владимировна, Д. С., & Shlyakhto, E. V. (2016) · Diabetes Mellitus · doi:10.14341/dm7192 · Cited by 12
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 9
“More recently, GLP-1 treated rats showed an improvement in behavioural score and smaller infarct volumes after stroke [74].”
BackgroundСиманенкова, А. В., Fuks, O., Тимкина, Н. В., Islamova, A., Суфиева, Д. А., Kirik, O. V., Korzhevsky, D. E., Vlasov, T. D., & Каронова, Т. Л. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907265 · Cited by 7
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
Duţă, C., Muscurel, C., Dogaru, C. B., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041516 · Cited by 8
“In another study, liraglutide was shown to reduce infarct volume and oxidative stress parameters by stimulating GLP-1Rs in stroke rat models [106].”
Singh, K., Gupta, J. K., Shrivastava, A., Jain, D., Yadav, A. P., Dwivedi, S., Dubey, A., & Kumar, S. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273316382240807120241 · Cited by 7
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Ferrari, F., Moretti, A., & Villa, R. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105018 · Cited by 6
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
“16,20 Across preclinical studies, neuroprotective effects have been linked to reduced infarct volume, apoptosis, oxidative stress, and inflammation, and to improvements in cerebral blood flow, neurogenesis, and angiogenesis, with functional benefits in cognitive and motor domains; these studies…”
Metadata
- Authors
- Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., Sasaki, T., Sasada, S., Kondo, A., Borlongan, C., Matsumae, M., & Date, I.
- Affiliations
- Tokai University (JP)
- Okayama University (JP)
- University of Kochi (JP)
- Department of Neurosurgery, University of South Florida College Medicine, Tampa, FL 12901, USA
- Corresponding author
- Yasuhara, Takao
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-10-30
- Volume
- 14
- Issue
- 11
- Pages
- 21513-21524
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3856019
- OpenAlex
- W2094706071
- Cited by
- 120
- References
- 30
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 11 · 2019: 13 · 2018: 18 · 2017: 10 · 2016: 10 · 2015: 17 · 2014: 4
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (23791602, 23390349)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, neuroprotection, stroke, cerebral ischemia, middle cerebral artery occlusion, GLP-1 analogues, oxidative stress, reactive oxygen species, vascular endothelial growth factor, infarct size, diabetes mellitus, reperfusion
- MeSH terms
- Liraglutide, Animals, Blood Glucose, Disease Models, Animal, Humans, Oxidative Stress, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Vascular Endothelial Growth Factor A, Diabetes Complications, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.